跳至主要内容
临床试验/NCT03310983
NCT03310983已完成不适用

Growth and Adiposity in Newborns: The Influence of Prenatal Docosahexaenoic Acid (DHA) Supplementation

University of Kansas Medical Center1 个研究点 分布在 1 个国家目标入组 254 人开始时间: 2017年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
254
试验地点
1
主要终点
Infant Fat Mass (FM)

研究概览

简要总结

The purpose of this study is to learn if participants in the ADORE study (NCT02626299), who took a DHA supplement during pregnancy, see favorable body fat in their infants from birth to 24 months, and if excessive or appropriate weight gain during pregnancy impacts this result.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Agree to consume study capsules and a typical prenatal supplement of 200 mg DHA
  • Available by telephone

排除标准

  • Expecting multiple infants
  • Gestational age at baseline <12 weeks or >20 weeks
  • Unable or unwilling to agree to consume capsules until delivery
  • Unwilling to discontinue use of another prenatal supplement with DHA that contains ≥ 200 mg DHA
  • Women with allergy to any component of DHA product (including algae), soybean oil or corn oil

结局指标

主要结局

Infant Fat Mass (FM)

时间窗: 24 months

Difference in FM in offspring exposed to high vs. low DHA and excessive vs. non-excessive GWG

次要结局

  • Central Fat Mass(24 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验